A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703
This study is recruiting at 30 US sites in 18 states, according to its ClinicalTrials.gov record last updated .
Summary
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cervical Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama- Birmingham ( Site 5015) · Birmingham, AL
Alaska · 1
- Alaska Womens Cancer Care ( Site 5046) · Anchorage, AK
California · 2
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5037) · Irvine, CA
- University of California Irvine Medical Center ( Site 6006) · Orange, CA
Florida · 4
- Florida Cancer Specialists - South ( Site 7001) · Fort Myers, FL
- Mount Sinai Braman Comprehensive Cancer Center ( Site 5043) · Miami Beach, FL
- Mount Sinai Comprehensive Cancer Center ( Site 6000) · Miami Beach, FL
- Florida Cancer Specialists - East ( Site 7000) · West Palm Beach, FL
Georgia · 2
- Winship Cancer Institute of Emory University ( Site 5005) · Atlanta, GA
- Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005) · Savannah, GA
Louisiana · 1
- TRIALS 365 ( Site 6008) · Shreveport, LA
Maryland · 1
- Maryland Oncology Hematology (MOH) ( Site 8001) · Columbia, MD
Minnesota · 1
- Minnesota Oncology Hematology, PA ( Site 8003) · Edina, MN
Nevada · 1
- Women's Cancer Center of Nevada ( Site 6011) · Las Vegas, NV
New York · 2
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5039) · Mineola, NY
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009) · New York, NY
Ohio · 1
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6002) · Columbus, OH
Oklahoma · 1
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001) · Tulsa, OK
Oregon · 1
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007) · Eugene, OR
Pennsylvania · 2
- Honickman Center ( Site 5033) · Philadelphia, PA
- Asplundh Cancer Pavilion ( Site 5002) · Willow Grove, PA
Rhode Island · 1
- Women & Infants Hospital ( Site 6003) · Providence, RI
Tennessee · 1
- University of Tennessee Medical Center ( Site 6012) · Knoxville, TN
Texas · 4
- Texas Oncology - DFW ( Site 8005) · Fort Worth, TX
- Houston Methodist Hospital-Obstetrics and Gynecology ( Site 6010) · Houston, TX
- Texas Oncology-The Woodlands ( Site 8000) · The Woodlands, TX
- Texas Oncology - Northeast Texas ( Site 8002) · Tyler, TX
Virginia · 3
- University of Virginia Cancer Center ( Site 5044) · Charlottesville, VA
- University of Virginia Cancer Center ( Site 6014) · Charlottesville, VA
- Inova Schar Cancer Institute ( Site 5045) · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.